Herzlich willkommen

Hier entsteht eine neue Website eines Kunden von cyon.

Patent opposition – Fundación GEP
8 11, 2022

Tenofovir Alafenamida (TAF): El INPI rechaza otra patente solicitada por Gilead

2022-11-08T16:50:18-03:00martes, 8 noviembre, 2022|Acceso a medicamentos, Access to Medicines, Intellectual Property, Oposiciones a patentes, Patent opposition|

La oficina de patentes argentina rechazó una nueva solicitud de patente de Tenofovir Alafenamida (TAF), con los argumentos planteados por la Fundación GEP. El rechazo de esta patente permitirá mejorar el acceso a este medicamento, cada vez más utilizado para la prevención y tratamiento del VIH.  Buenos Aires, 31 de octubre de 2022.  El Tenofovir

17 12, 2015

FGEP continues defense of public health in Argentina against the abuse of the patent system by multinational pharmaceutical companies

2015-12-17T03:50:58-03:00jueves, 17 diciembre, 2015|Access to Medicines, Argentina, Direct Action, Health Safeguards, HIV, Intellectual Property, Kaletra, Patent opposition, Sofosbuvir|

BUENOS AIRES, December 15th 2015 - Fundación Grupo Efecto Positivo (FGEP), an organization whose work is focused on guaranteeing access to essential medicines for HIV and Hepatitis C in Argentina and Latin America, announced in a press conference on November 30th two new key actions to defend public health policies. Dr. Daniel Gollán, Argentina’s Minister

10 11, 2015

Regulatory Agency in Argentina approved sofosbuvir and a local pharmaceutical company announced the entry into the market of its generic version

2015-11-14T16:07:28-03:00martes, 10 noviembre, 2015|Hepatitis C, Medicines, Patent opposition, Sofosbuvir|

Buenos Aires, November 10, 2015 - Argentine Medicines Regulatory Agency, ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) approved last week commercialization of a relevant medicine to treat Hepatitis C. “This measure was highly expected since it is the first step to ensure availability of this essential medicine in our country. I live with Hepatitis

4 11, 2015

Argentina could save U$11M per year buying generic version of Truvada®

2015-11-04T20:01:06-03:00miércoles, 4 noviembre, 2015|Access to Medicines, Advocacy, Health Safeguards, Intellectual Property, Patent opposition|

The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine

27 08, 2015

People living with HepC denounced high prices of the pharmaceutical industry

2015-11-04T20:18:54-03:00jueves, 27 agosto, 2015|Direct Action, Hepatitis C, Intellectual Property, Patent opposition, Public Health|

Buenos Aires, August 27th 2015 - Members of Grupo Efecto Positivo Foundation (FGEP) accompanied by other civil society organizations and representatives held a direct action during the 2015 Hepatitis International Symposium organized by Fundación Huesped. The action aimed to denounce monopolies and high prices of drugs to treat hepatitis C and took place during the presentation of Dr.

Ir a Arriba